Gilead Sciences

Cognizant declared the growth of its partnership with biopharmaceutical firm Gilead Sciences for an additional five years, which includes renewal and growth of Cognizant's services, for a total projected value of $800 million. Under the deal, the NASDAQ-listed IT firm will manage Gilead’s global IT infrastructure, platforms, applications, and advanced analytics and lead initiatives to…

EVERSANA, a leading provider of commercial services to the global life sciences industry, announced that it will team up with Amazon Web Services (AWS) to accelerate generative artificial intelligence (AI) use cases across the life sciences industry. Together, the organisations will seek to harness the power of generative AI to help pharmaceutical and life science manufacturers drive…

Gilead Sciences has expanded its existing collaboration with IT company Cognizant in a bid to more quickly bring drugs to market, with the new five-year service agreement worth approximately $800m. The partnership will see Cognizant manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and take charge of initiatives designed to accelerate the US…

Gilead Sciences (NASDAQ:GILD - Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, August 3rd. Analysts expect the company to announce earnings of $1.63 per share for the quarter. Parties that wish to register for the company's conference call can do so using this link. Gilead…

Gilead Sciences (GILD) closed at $77.19 in the latest trading session, marking a -0.05% move from the prior day. This change lagged the S&P 500's 0.02% loss on the day. At the same time, the Dow added 0.23%, and the tech-heavy Nasdaq lost 0.12%. Heading into today, shares of the HIV and hepatitis C drugmaker…

Cognizant has announced an extension of its partnership with Gilead Sciences, which will see Cognizant lead digital transformation at Gilead, among additional expansions, for a total expected value of US$800m over the following five years. Gilead will use these advancements to market medicine for HIV, viral hepatitis and cancer. A partnership to advance healthcare technology…

In reporting its first-quarter earnings, Biogen said it would halt the development of at least four investigational drugs to allow the company to focus on more lucrative opportunities. | In a sizable cost-cutting measure, Biogen will lay off 1,000 employees by 2025, it announced in presenting its second quarter earnings. With the company starting…

Nataliya Smirnova, Unsplash Cognizant has expanded its relationship with biopharmaceutical company Gilead Sciences to leverage…

Seattle biotech startup A-Alpha Bio raised $22.4 million to boost development of its machine learning platform that analyzes protein-protein interactions. A-Alpha Bio, a spinout of the Institute for Protein Design… Read More

The news should boost the IT services industry, which is struggling with declining demand as clients put off less important projects. On Monday, Cognizant made an announcement that it was extending its IT service agreement with Gilead Sciences for an additional $800 million in estimated value over the following five years, continuing the current pattern…

In keeping with the recent trend of software majors bagging big deals, Cognizant on Monday said it is expanding its IT service partnership with Gilead Sciences for a total expected value of $800 million over the next five years. In June, Tata Consultancy Services (TCS) pulled of a $1 billion deal win from UK’s Nest,…

by Ty Trumbull • Jul 24, 2023 Cognizant has expanded its collaboration with Gilead Sciences, a prominent biopharmaceutical company, in a partnership valued at $800 million over the next five years. The new agreement involves Cognizant managing Gilead’s global IT infrastructure, platforms, applications, and advanced analytics, with a focus on accelerating its digital transformation. The…